CAR T Cell Toxicity: Current Management and Future Directions

Overview

Journal Hemasphere

Publisher Wiley

Specialty Hematology

Date 2019 Nov 15

PMID 31723825

Citations 74

Authors

Lucrecia Yanez

Miriam Sanchez-Escamilla

Miguel-Angel Perales

Affiliations

Soon will be listed here.

Abstract

By late 2018, 2 chimeric antigen receptor T (CAR T) cell products have been approved by US and European regulatory authorities. Tisagenlecleucel (Kymriah, Novartis) is indicated in the treatment of patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse, or adult patients with large B-cell lymphoma relapsed or refractory (r/r) after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Axicabtagene ciloleucel (Yescarta, Kite) is indicated for the treatment of adult patients with large B-cell lymphoma relapsed or refractory after 2 or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (ZUMA-1 trial). This review will offer a practical guide for the recognition and management of the most important toxicities related to the use of the current commercial CAR T cells, and also highlight strategies to diminish these side effects in the future.

Citing Articles

Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.

Bock T, Colonne C, Fiorenza S, Turtle C Nat Rev Clin Oncol. 2025; .

PMID: 39966627 DOI: 10.1038/s41571-025-00992-5.

Unraveling the complexity of follicular lymphoma: insights and innovations.

Li X, Li N, Liu Y, An L Am J Cancer Res. 2025; 14(12):5573-5597.

PMID: 39803651 PMC: 11711519. DOI: 10.62347/MFUG2190.

Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination.

Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R J Adv Pract Oncol. 2025; 1-16.

PMID: 39802527 PMC: 11715450. DOI: 10.6004/jadpro.2024.15.8.15.

Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.

Bradley T, Davis M, Martin J, Woodward S J Adv Pract Oncol. 2025; 1-16.

PMID: 39802526 PMC: 11715511. DOI: 10.6004/jadpro.2024.15.8.21.

The bidirectional interplay between T cell-based immunotherapies and the tumor microenvironment.

Pherez-Farah A, Boncompagni G, Chudnovskiy A, Pasqual G Cancer Immunol Res. 2025; .

PMID: 39786986 PMC: 7617322. DOI: 10.1158/2326-6066.CIR-24-0857.

References

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331. PMC: 5482103. DOI: 10.1182/blood-2017-02-769208. View

Burstein D, Maude S, Grupp S, Griffis H, Rossano J, Lin K . Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. Biol Blood Marrow Transplant. 2018; 24(8):1590-1595. DOI: 10.1016/j.bbmt.2018.05.014. View

Le R, Li L, Yuan W, Shord S, Nie L, Habtemariam B . FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018; 23(8):943-947. PMC: 6156173. DOI: 10.1634/theoncologist.2018-0028. View

Turtle C, Hanafi L, Berger C, Hudecek M, Pender B, Robinson E . Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016; 8(355):355ra116. PMC: 5045301. DOI: 10.1126/scitranslmed.aaf8621. View

Davila M, Kloss C, Gunset G, Sadelain M . CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One. 2013; 8(4):e61338. PMC: 3621858. DOI: 10.1371/journal.pone.0061338. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F . Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017; 15(1):47-62. PMC: 6733403. DOI: 10.1038/nrclinonc.2017.148. View

Gust J, Hay K, Hanafi L, Li D, Myerson D, Gonzalez-Cuyar L . Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017; 7(12):1404-1419. PMC: 5718945. DOI: 10.1158/2159-8290.CD-17-0698. View

10.

Brudno J, Kochenderfer J . Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127(26):3321-30. PMC: 4929924. DOI: 10.1182/blood-2016-04-703751. View

11.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24(6):739-748. DOI: 10.1038/s41591-018-0036-4. View

12.

Li H, Zhao Y . Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein Cell. 2017; 8(8):573-589. PMC: 5546931. DOI: 10.1007/s13238-017-0411-9. View

13.

Zyuzkov G, Guryantseva L, Simanina E, Zhdanov V, Dygai A, Goldberg E . Effect of dimethylsulfoxide on the functions of mesenchymal and hemopoietic precursors. Bull Exp Biol Med. 2008; 143(4):535-8. DOI: 10.1007/s10517-007-0173-0. View

14.

Ramos C, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O . Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016; 126(7):2588-96. PMC: 4922690. DOI: 10.1172/JCI86000. View

15.

Chu F, Cao J, Neelalpu S . Versatile CAR T-cells for cancer immunotherapy. Contemp Oncol (Pozn). 2018; 22(1A):73-80. PMC: 5885071. DOI: 10.5114/wo.2018.73892. View

16.

Zeiser R, Blazar B . Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179. PMC: 6034180. DOI: 10.1056/NEJMra1609337. View

17.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

18.

Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T . Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018; 173(6):1439-1453.e19. PMC: 6003425. DOI: 10.1016/j.cell.2018.05.013. View

19.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

20.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View